FDA Panel Backs 6 of 7 Peptides for Compounding — Vote Is Not Binding
The Pharmacy Compounding Advisory Committee met on July 23–24, 2026 and voted to recommend six of the seven peptides it reviewed for the Section 503A bulk drug substances list — the list that governs what compounding pharmacies may legally prepare. BPC-157 and KPV each cleared 8–6, with TB-500 and MOTS-c also backed. On the second day Epitalon was recommended and Semax 8–5, while Emideltide (DSIP) was rejected 6–7. The panel voted against the recommendation of the FDA’s own scientists, who had argued the human safety data was insufficient.
What's official: the advisory committee has voted and its recommendations are on the record. Six peptides were backed for the 503A list, one was rejected.
Nothing has changed legally. The vote is a non-binding recommendation. Until the FDA completes rulemaking, these peptides remain off the 503A list, compounding them is still not permitted, and selling them for human use still violates the FDCA.
Peptide Laws in United States
US · Americas · 24 peptides tracked
Are Peptides Legal in United States?
The United States regulates peptides under FDA oversight. The major development: on 30 October 2026 HHS published an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register doc 2026-22192, docket HHS-OASH-2026-0496). HHS will not take enforcement action against a state-licensed pharmacy, federal facility or licensed physician who compounds BPC-157, TB-500, Epitalon, KPV, MOTS-c or Semax under Section 503A, provided ten conditions are met. This is enforcement discretion, not approval: none of the six is FDA-approved, none has been added to the Section 503A bulk drug substances list, and the policy does not extend to Section 503B outsourcing facilities. A patient-specific prescription is still required. Critically, a compounded product may contain only ONE active ingredient, so multi-peptide stacks such as BPC-157 with TB-500 are outside the policy despite widespread reporting to the contrary. The bulk substance must come from an FDA-registered, CGMP-compliant facility with a certificate of analysis, serious adverse events must go to FDA MedWatch, and labelling must read "This is a compounded drug product. Not for resale." The policy runs until the FDA completes notice-and-comment rulemaking on the bulks list, and HHS may revisit it if a safety or quality signal emerges; public comments close around 13 November 2026. The six were recommended by the Pharmacy Compounding Advisory Committee at its 23-24 July 2026 meeting, against the advice of FDA's own review scientists. Emideltide (DSIP) was reviewed at the same meeting and rejected, so it remains barred from compounding. Buying any of these as a "research chemical" for human use remains unlawful. No peptide has been DEA-scheduled as a controlled substance. The FDA continues to enforce aggressively against compounded GLP-1 drugs (semaglutide, tirzepatide), with 85+ warning letters issued. Research-use-only labelling requirements have been fully enforceable since January 2026.
3
Legal9
Grey Area12
PrescriptionCan You Buy Peptides in United States?
3 peptide(s) are legal to buy in United States, including NAD+, Glutathione, Vitamin B12. 12 peptide(s) require a valid prescription, including Tirzepatide, MOTS-c, TB-500, Semaglutide, Semax, and 7 more. 9 peptide(s) fall into a legal grey area: Retatrutide, Selank, AOD-9604, GHK-Cu, Ipamorelin, and 4 more. These may be available for research purposes but their legality for personal use is ambiguous.
Traveling to United States with Peptides
When traveling to United States with peptides, the legality depends on each peptide's classification. Prescription peptides (Tirzepatide, MOTS-c, TB-500, Semaglutide, Semax, and 7 more) typically require documentation such as a prescription or doctor's letter when crossing borders. Enforcement in United States is rated as "Moderate." Always declare pharmaceutical products at customs and carry documentation of any prescriptions.
New to peptides? Start with the basics on peptide.camp →
Need to source peptides for United States? Get verified wholesale quotes on peptide.broker →
Traveling to United States with peptides? TSA tips, packing guides & the peptide travel case on peptide.travel →
Peptide Regulations in United States
| Peptide | Status | Rx Required | Schedule | Detail | Source |
|---|---|---|---|---|---|
| Tirzepatide | Prescription | Yes | Not Scheduled | FDA-approved prescription drug. Brand names: Mounjaro (diabetes), Zepbound (obesity). Dual GIP/GLP-1 agonist. Same compounding enforcement pattern as semaglutide. | Official |
| MOTS-c | Prescription | Yes | Not Scheduled | Not FDA-approved and NOT on the Section 503A bulk drug substances list. Since 30 Oct 2026, HHS will not take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding this peptide under Section 503A, provided all ten conditions in the policy are met. A patient-specific prescription is still required: the policy does not waive Section 503A's prescription requirement. Key limits: the compounded product may contain only ONE active ingredient, so multi-peptide stacks (for example BPC-157 with TB-500) fall outside the policy; the identity and route of administration must match the policy appendix; the bulk substance must come from an FDA-registered, CGMP-compliant facility with a valid certificate of analysis; serious adverse events must be reported to FDA MedWatch; labelling must state "This is a compounded drug product. Not for resale."; any packaged delivery device must be a 510(k)-cleared syringe. The policy does NOT extend to Section 503B outsourcing facilities, does NOT add the substance to the 503A bulks list and does NOT constitute FDA approval. It runs until the FDA completes notice-and-comment rulemaking on the 503A bulks list, and HHS may revisit it if a safety or product-quality signal arises. Buying this peptide as a "research chemical" for human use remains unlawful. | Official |
| Retatrutide | Grey Area | No | Not Scheduled | Investigational new drug. Not FDA-approved. Not yet on Category 2 list. Available from research chemical vendors. FDA has not specifically targeted retatrutide enforcement yet. Framework: selling an unapproved new drug for human use violates 21 U.S.C. 331(d) and 355(a). A bare violation is a misdemeanour under 333(a)(1); adding intent to defraud or mislead under 333(a)(2) makes it a three-year felony. No peptide is a federally scheduled controlled substance as of the DEA list revised 27 August 2026. | Official |
| Selank | Grey Area | No | Not Scheduled | Not specifically regulated by FDA. Available as research peptide. Originally developed in Russia where it is an approved anxiolytic. Minimal US enforcement attention. | Secondary |
| AOD-9604 | Grey Area | No | Not Scheduled | On FDA Category 2 list. Cannot be compounded. Available from research vendors. Anti-obesity peptide (GH fragment). | Secondary |
| TB-500 | Prescription | Yes | Not Scheduled | Not FDA-approved and NOT on the Section 503A bulk drug substances list. Since 30 Oct 2026, HHS will not take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding this peptide under Section 503A, provided all ten conditions in the policy are met. A patient-specific prescription is still required: the policy does not waive Section 503A's prescription requirement. Key limits: the compounded product may contain only ONE active ingredient, so multi-peptide stacks (for example BPC-157 with TB-500) fall outside the policy; the identity and route of administration must match the policy appendix; the bulk substance must come from an FDA-registered, CGMP-compliant facility with a valid certificate of analysis; serious adverse events must be reported to FDA MedWatch; labelling must state "This is a compounded drug product. Not for resale."; any packaged delivery device must be a 510(k)-cleared syringe. The policy does NOT extend to Section 503B outsourcing facilities, does NOT add the substance to the 503A bulks list and does NOT constitute FDA approval. It runs until the FDA completes notice-and-comment rulemaking on the 503A bulks list, and HHS may revisit it if a safety or product-quality signal arises. Buying this peptide as a "research chemical" for human use remains unlawful. | Official |
| GHK-Cu | Grey Area | No | Not Scheduled | Not specifically targeted by FDA. Available as research peptide. Topical formulations widely sold in cosmetics. Less enforcement attention than BPC-157/TB-500. | Secondary |
| Ipamorelin | Grey Area | No | Not Scheduled | Same status as CJC-1295. Removed from Category 2 list Sept 2024. Under PCAC review. Cannot be legally compounded pending outcome. | Unofficial |
| Semaglutide | Prescription | Yes | Not Scheduled | FDA-approved prescription drug. Brand names: Ozempic (diabetes), Wegovy (obesity). Compounding was temporarily allowed during shortage but FDA cracking down on compounded versions. Novo Nordisk actively suing compounding pharmacies. | Official |
| CJC-1295 | Grey Area | No | Not Scheduled | Removed from Category 2 prohibited list Sept 2024 after nominators withdrew. NOT cleared for compounding — under PCAC review. Cannot be legally compounded pending review outcome. | Unofficial |
| Semax | Prescription | Yes | Not Scheduled | Not FDA-approved and NOT on the Section 503A bulk drug substances list. Since 30 Oct 2026, HHS will not take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding this peptide under Section 503A, provided all ten conditions in the policy are met. A patient-specific prescription is still required: the policy does not waive Section 503A's prescription requirement. Key limits: the compounded product may contain only ONE active ingredient, so multi-peptide stacks (for example BPC-157 with TB-500) fall outside the policy; the identity and route of administration must match the policy appendix; the bulk substance must come from an FDA-registered, CGMP-compliant facility with a valid certificate of analysis; serious adverse events must be reported to FDA MedWatch; labelling must state "This is a compounded drug product. Not for resale."; any packaged delivery device must be a 510(k)-cleared syringe. The policy does NOT extend to Section 503B outsourcing facilities, does NOT add the substance to the 503A bulks list and does NOT constitute FDA approval. It runs until the FDA completes notice-and-comment rulemaking on the 503A bulks list, and HHS may revisit it if a safety or product-quality signal arises. Buying this peptide as a "research chemical" for human use remains unlawful. | Official |
| BPC-157 | Prescription | Yes | Not Scheduled | Not FDA-approved and NOT on the Section 503A bulk drug substances list. Since 30 Oct 2026, HHS will not take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding this peptide under Section 503A, provided all ten conditions in the policy are met. A patient-specific prescription is still required: the policy does not waive Section 503A's prescription requirement. Key limits: the compounded product may contain only ONE active ingredient, so multi-peptide stacks (for example BPC-157 with TB-500) fall outside the policy; the identity and route of administration must match the policy appendix; the bulk substance must come from an FDA-registered, CGMP-compliant facility with a valid certificate of analysis; serious adverse events must be reported to FDA MedWatch; labelling must state "This is a compounded drug product. Not for resale."; any packaged delivery device must be a 510(k)-cleared syringe. The policy does NOT extend to Section 503B outsourcing facilities, does NOT add the substance to the 503A bulks list and does NOT constitute FDA approval. It runs until the FDA completes notice-and-comment rulemaking on the 503A bulks list, and HHS may revisit it if a safety or product-quality signal arises. Buying this peptide as a "research chemical" for human use remains unlawful. | Official |
| NAD+ | Legal | No | Not Scheduled | NAD+ (nicotinamide adenine dinucleotide) has unique status. Oral supplements (NMN/NR precursors) sold freely as dietary supplements. IV NAD+ infusions offered at wellness clinics under medical supervision. Not specifically targeted by FDA for enforcement. | Secondary |
| DSIP | Grey Area | No | Not Scheduled | Barred from Section 503A compounding. Emideltide (DSIP) was reviewed by the FDA Pharmacy Compounding Advisory Committee at its 23-24 July 2026 meeting and was NOT recommended (reported tally 6-7 with 1 abstention). It is excluded from the HHS enforcement discretion policy of 30 October 2026, which covers only BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. DSIP therefore remains an unapproved drug that may not lawfully be compounded, and is not on the 503A bulk drug substances list. | Official |
| Epithalon | Prescription | Yes | Not Scheduled | Also written Epitalon; the HHS policy uses the spelling "Epitalon". Not FDA-approved and NOT on the Section 503A bulk drug substances list. Since 30 Oct 2026, HHS will not take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding this peptide under Section 503A, provided all ten conditions in the policy are met. A patient-specific prescription is still required: the policy does not waive Section 503A's prescription requirement. Key limits: the compounded product may contain only ONE active ingredient, so multi-peptide stacks fall outside the policy; the identity and route of administration must match the policy appendix; the bulk substance must come from an FDA-registered, CGMP-compliant facility with a valid certificate of analysis; serious adverse events must be reported to FDA MedWatch; labelling must state "This is a compounded drug product. Not for resale."; any packaged delivery device must be a 510(k)-cleared syringe. The policy does NOT extend to Section 503B outsourcing facilities, does NOT add the substance to the 503A bulks list and does NOT constitute FDA approval. It runs until the FDA completes notice-and-comment rulemaking on the 503A bulks list, and HHS may revisit it if a safety or product-quality signal arises. Buying this peptide as a "research chemical" for human use remains unlawful. | Official |
| Glutathione | Legal | No | Supplement | Oral form: GRAS status (GRN 000244), sold as dietary supplement under DSHEA. Injectable form: No FDA-approved product. Available via compounding pharmacies with prescription. FDA has sought to restrict compounded glutathione (PCAC 2022 review). | Official |
| HGH | Prescription | Yes | Not Scheduled | FDA-approved (Genotropin, Norditropin, Humatrope, Omnitrope, Saizen, Skytrofa, Sogroya). Not DEA-scheduled but distribution for non-medical use is a federal felony under 21 USC 333(e) (up to 5 years imprisonment). Compounding permitted under 503A with USP monograph. | Official |
| KPV | Prescription | Yes | Not Scheduled | Not FDA-approved and NOT on the Section 503A bulk drug substances list. Since 30 Oct 2026, HHS will not take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding this peptide under Section 503A, provided all ten conditions in the policy are met. A patient-specific prescription is still required: the policy does not waive Section 503A's prescription requirement. Key limits: the compounded product may contain only ONE active ingredient, so multi-peptide stacks (for example BPC-157 with TB-500) fall outside the policy; the identity and route of administration must match the policy appendix; the bulk substance must come from an FDA-registered, CGMP-compliant facility with a valid certificate of analysis; serious adverse events must be reported to FDA MedWatch; labelling must state "This is a compounded drug product. Not for resale."; any packaged delivery device must be a 510(k)-cleared syringe. The policy does NOT extend to Section 503B outsourcing facilities, does NOT add the substance to the 503A bulks list and does NOT constitute FDA approval. It runs until the FDA completes notice-and-comment rulemaking on the 503A bulks list, and HHS may revisit it if a safety or product-quality signal arises. Buying this peptide as a "research chemical" for human use remains unlawful. | Official |
| Liraglutide | Prescription | Yes | Not Scheduled | FDA-approved: Victoza (diabetes, 2010), Saxenda (weight, 2014). Generic liraglutide approved 2024 (Victoza) and Aug 2025 (Saxenda). Category 2 (do-not-compound). Compounding discretion windows closed (503A Apr 2025, 503B May 2025). | Official |
| Melanotan II | Grey Area | No | Not Scheduled | Not FDA-approved. FDA has issued explicit warnings about Melanotan products as unapproved drugs and misbranded cosmetics. Was on Category 2 list. HHS announced Feb 2026 reclassification to Category 1 (pending). Enforcement actions include seizures and warning letters. | Official |
| PT-141 | Prescription | Yes | Not Scheduled | FDA-approved: Vyleesi (bremelanotide, June 2019) for HSDD in premenopausal women only. Not a controlled substance. Category 2 (do-not-compound). HHS announced Feb 2026 potential reclassification to Category 1 (pending). | Official |
| MK-677 | Grey Area | No | Not Scheduled | Not FDA-approved. Not DEA-scheduled. Investigational New Drug (Merck). FDA issued warning letters Dec 2025 to companies marketing MK-677 as supplements. Sold as research chemical. | Official |
| Vitamin B12 | Legal | No | Supplement | Oral/sublingual: GRAS dietary supplement (21 CFR 184.1945). Injectable: FDA-approved prescription drug (cyanocobalamin injection). Nasal spray (Nascobal) also Rx. | Official |
| Epitalon | Prescription | Yes | Not Scheduled | Not FDA-approved and NOT on the Section 503A bulk drug substances list. Since 30 Oct 2026, HHS will not take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding this peptide under Section 503A, provided all ten conditions in the policy are met. A patient-specific prescription is still required: the policy does not waive Section 503A's prescription requirement. Key limits: the compounded product may contain only ONE active ingredient, so multi-peptide stacks (for example BPC-157 with TB-500) fall outside the policy; the identity and route of administration must match the policy appendix; the bulk substance must come from an FDA-registered, CGMP-compliant facility with a valid certificate of analysis; serious adverse events must be reported to FDA MedWatch; labelling must state "This is a compounded drug product. Not for resale."; any packaged delivery device must be a 510(k)-cleared syringe. The policy does NOT extend to Section 503B outsourcing facilities, does NOT add the substance to the 503A bulks list and does NOT constitute FDA approval. It runs until the FDA completes notice-and-comment rulemaking on the 503A bulks list, and HHS may revisit it if a safety or product-quality signal arises. Buying this peptide as a "research chemical" for human use remains unlawful. | Official |
About the sources on this page
Entries marked Official cite a government regulator, legislation or an official gazette. Entries marked Secondary rest on consultancy, law firm, news or academic reporting rather than the regulator itself. Entries marked Unofficial rest on sources that are not authoritative — which may include commercial sellers, medicine-import services or independent websites.
We show these entries rather than hiding them, but they should not be relied on. Nothing on this site is legal advice. Verify against the national regulator before acting, and if you can point us at a better source please submit an update.
Data is researcher-verified but not legal advice. Always consult local regulations before purchasing, importing, or traveling with peptides. Last verified: 2026-02-28.